Prior to that, Carson served as President and CEO of OPDC (2010-2019) having co-founded Otsuka’s presence in Princeton, NJ in 2002 to support the launch of Abilify in partnership with Bristol-Myers Squibb. Under his leadership, Otsuka was able to launch the Abilify follow-on, Rexulti, and Jynarque for polycystic kidney disease and ultimately the first FDA-approved digital medicine, Abilify MyCite.
Born and raised in Columbia, S.C., Carson graduated from Harvard College. He received his M.D. degree from Case Western Reserve University and did his psychiatry residency at Tufts/New England Medical Center. Prior to joining industry, he was a faculty member in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina from 1988-1998.
Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business. Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew.
Kabir holds an MA from King's College, University of Cambridge, and an MBA with Distinction from INSEAD.
Before coming to Otsuka, Mary spent nine years with Wyeth Pharmaceuticals in Opinion Leader and Advocacy Relations, where she developed and executed our Global Opinion Leader business strategies across the Specialty products portfolio. Prior to Wyeth, Mary was at Bristol-Myers Squibb for 13 years, in a variety of positions. At Otsuka, she has spearheaded the launch of the Global Council on Alzheimer’s Disease (GCAD), a collection of preeminent experts who influence the Alzheimer’s space, including science, medicine, technology, policy, advocacy, and caregiving. Through GCAD, Mary has jumpstarted technological innovation, framed a patient navigation model for Alzheimer’s, and helped improve communications between families and healthcare providers.
Mary is a graduate of Virginia Tech as well as Singularity University.
Before joining the nonprofit sector, Melissa was a litigator, working as a prosecutor in the Brooklyn DA's Office and as a criminal defense attorney. She was also an adjunct professor of Nonprofit Management at New York University’s Wagner School of Public Service and an adjunct professor in the Political Science Department at Fordham University.
Melissa has authored numerous articles on nonprofit management and social justice issues, and has participated in many panel discussions and debates. She also holds volunteer leadership positions for several nonprofit organizations including the Correctional Association of New York and The Support Center on Nonprofit Management.
A graduate of Hampshire College, Melissa earned her JD from the Benjamin N. Cardozo School of Law and holds a certificate in nonprofit management from the Columbia Business School.